FDA scolds Novartis over a misleading TV ad for a breast cancer treatment ; The necessary roughness of 2023 has set up a very promising 2024 for biotech jobs

Taking stock of the drug industry, from the lab to the medicine chest

January 19, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Ruby Wallau for STAT STAT+ | FDA scolds Novartis over a misleading TV ad for a breast cancer treatment This is the eighth consecutive letter in which FDA took issue with ads or promotions that touted the effectiveness of a medicine. By Ed Silverman STAT+ | Opinion: The necessary roughness of 2023 has set up a very promising 2024 for biotech jobs A partner at an executive search firm writes that his recent JPM24 experience is making him optimistic about the year ahead in biotech jobs. By Christopher Palatucci STAT+ | The FDA's diagnostics chief, who led through Covid, has retired Timothy Stenzel, who led the FDA's diagnostics division during the Covid-19 pandemic, has left the agency. He retired at the end of 2023. By Lizzy Lawrence Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser